Traws Pharma, Inc. (NASDAQ:TRAW) Given Consensus Rating of “Reduce” by Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have been given an average recommendation of “Reduce” by the five analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $1.00.

Several brokerages recently commented on TRAW. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. Citigroup lowered Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a report on Tuesday, August 18th. LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a research report on Wednesday, August 26th.

Traws Pharma Stock Up 1.5%

NASDAQ:TRAW opened at $0.55 on Friday. The firm has a market capitalization of $8.45 million, a PE ratio of -0.32 and a beta of 1.60. Traws Pharma has a 12-month low of $0.43 and a 12-month high of $3.27. The firm has a 50-day moving average price of $0.60 and a 200 day moving average price of $1.21.

Traws Pharma (NASDAQ:TRAW) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18. On average, research analysts expect that Traws Pharma will post -1.2 EPS for the current year.

Institutional Trading of Traws Pharma

Hedge funds have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its stake in shares of Traws Pharma by 121.2% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after acquiring an additional 400,000 shares during the last quarter. Squadron Capital Management LLC acquired a new stake in Traws Pharma during the 4th quarter valued at $806,000. Ikarian Capital LLC raised its position in Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock valued at $766,000 after purchasing an additional 649,649 shares during the last quarter. Boothbay Fund Management LLC bought a new position in Traws Pharma in the 4th quarter valued at $220,000. Finally, ADAR1 Capital Management LLC acquired a new position in Traws Pharma in the fourth quarter worth $175,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.